8-K: BioSig Technologies Faces Nasdaq Delisting Warning Due to Low Share Price

BioSig Technologies received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement for continued listing.

Summary

• BioSig Technologies, Inc. received a letter from Nasdaq on April 11, 2025, indicating that it does not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market.
• This non-compliance is based on the closing bid price of the company's common stock for the 30 consecutive business day period between February 27, 2025, and April 10, 2025.
• BioSig has been granted a compliance period of 180 calendar days, until October 8, 2025, to regain compliance.
• To regain compliance, the company's common stock must maintain a minimum closing bid price of $1.00 for at least ten consecutive business days during this period.
• If the company fails to regain compliance within the initial 180-day period, it may be eligible for an additional 180 days if it meets certain requirements, including maintaining the market value of its publicly held shares and meeting all other initial listing standards except the bid price.
• The company may need to effect a reverse stock split to cure the deficiency during the second compliance period.
• If the company is unable to cure the deficiency or is ineligible for the additional cure period, Nasdaq will provide notice that the company's common stock will be subject to delisting, which the company may appeal.
• The notification does not immediately impact the listing of BioSig's common stock, which will continue to be listed and traded on The Nasdaq Capital Market, subject to compliance with other listing requirements.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting warning, indicating potential financial instability and uncertainty about the company's future.

Positives

• BioSig Technologies has been granted a 180-day compliance period to regain compliance with Nasdaq's minimum bid price requirement.
• The company may be eligible for an additional 180-day compliance period if it meets certain requirements.
• The company has the option to appeal a delisting determination to a hearings panel.

Negatives

• BioSig Technologies has received a delisting warning from Nasdaq due to its stock price falling below $1.00 for 30 consecutive business days.
• There is no assurance that the company will be able to regain compliance with Nasdaq's minimum bid price requirement within the given compliance period.
• If the company fails to regain compliance and its appeal is unsuccessful, its common stock will be delisted from The Nasdaq Capital Market.

Risks

• The company's stock price may continue to decline, making it difficult to regain compliance with Nasdaq's minimum bid price requirement.
• The company may not meet the requirements for an additional compliance period.
• The company's appeal of a delisting determination may be unsuccessful.
• Delisting from The Nasdaq Capital Market could negatively impact the company's stock price and its ability to raise capital.

Future Outlook

The company must regain compliance with Nasdaq's minimum bid price requirement by October 8, 2025, or potentially face delisting, although they may be eligible for an extension.

Industry Context

Delisting warnings are not uncommon for smaller companies, particularly in volatile sectors like biotechnology, and often lead to companies undertaking measures such as reverse stock splits to boost share prices and maintain listing compliance.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges with maintaining Nasdaq listing requirements.
• Reverse stock splits are a common strategy employed by companies like BioSig to increase their share price and avoid delisting, although the long-term impact on shareholder value can be mixed.
• Companies like Diffusion Pharmaceuticals and Citius Pharmaceuticals have faced similar delisting warnings and have implemented strategies to regain compliance.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is delisted.
• Employees may face uncertainty about their job security if the company's financial situation worsens.
• The company's ability to raise capital may be negatively impacted if it is delisted.

Next Steps

• BioSig Technologies must take steps to increase its stock price to at least $1.00 for ten consecutive business days before October 8, 2025.
• The company may consider a reverse stock split to increase its share price.
• The company may need to meet the continued listing requirement for the market value of its publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split if necessary.
• The company may appeal a delisting determination to a hearings panel.

Key Dates

Keywords

delisting, Nasdaq, compliance, minimum bid price, BioSig Technologies, stock price